Market Overview

UPDATE: Morgan Stanley Reiterates On McKesson Following Investor Day

Related MCK
Who Will Feel The Pain From Generic Drug Price Inflation?
McKesson Launches Venture Fund, Appoints Tom Rodgers As Managing Director

In a report published Thursday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on McKesson (NYSE: MCK), and raised the price target from $197.00 to $205.00.

In the report, Morgan Stanley noted, “Investor day showcased MCK's mkt leadership, favorable ind trends and mgmt breadth. Incr margin targets highlight expansion levers, complemented by cap deployment. W/ strong generic inflation, Celesio & PSS synergies, and generic scale oppty, we view MCK as best positioned in group. PT to $205.”

McKesson closed on Wednesday at $187.35.

Latest Ratings for MCK

DateFirmActionFromTo
Oct 2014Deutsche BankMaintainsBuy
Oct 2014JP MorganMaintainsOverweight
Sep 2014BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (MCK)

Around the Web, We're Loving...

Get Benzinga's Newsletters